Migalastat for Fabry Disease

Recruiting at 17 trial locations

Overseen By Amicus Therapeutics Patient Advocacy

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Amicus Therapeutics

Must not be taking: Miglitol, Agalsidase, Miglustat

Disqualifiers: Kidney transplant, Peritoneal dialysis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 8 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 2

Duration: 12 months

14 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial requires that you do not take certain medications like Glyset, Replagal, Fabrazyme, or Zavesca while participating. If you are on these, you would need to stop them to join the trial.

What data supports the effectiveness of the drug Migalastat for Fabry Disease?

Migalastat has been shown to be effective in treating Fabry disease by increasing the activity of a specific enzyme that is deficient in patients with this condition. Clinical trials have demonstrated that it can reduce heart size and stabilize kidney function in patients with certain genetic mutations, making it a valuable treatment option for those with amenable mutations. ^{1 2 3 4 5}

Is Migalastat safe for humans?

Research shows that Migalastat has been used in patients with Fabry disease for over 8 years, and it generally maintains kidney function without significant safety concerns. This suggests that it is generally safe for human use in this context. ^{6 7 8 9 10}

How is the drug migalastat unique in treating Fabry disease?

Migalastat is unique because it is an oral drug that acts as a pharmacological chaperone, stabilizing specific mutant forms of the enzyme α-galactosidase A, which helps it function properly in patients with certain genetic mutations. Unlike traditional enzyme replacement therapies that require intravenous infusions, migalastat offers a more convenient oral administration for those with amenable mutations. ^{1 2 4 11 12}

What is the purpose of this trial?

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)

Research Team

Clinical Research

Principal Investigator

Amicus Therapeutics

Eligibility Criteria

This trial is for adults with Fabry disease and severe kidney impairment, including those on stable hemodialysis. Participants must have a specific GLA gene variant treatable by migalastat and agree to use contraception if of reproductive potential. Exclusions include pregnancy, breastfeeding, unstable heart conditions, recent other investigational drugs or gene therapy, allergy to migalastat or similar drugs.

Inclusion Criteria

If of reproductive potential, both male and female patients agree to use a medically accepted method of contraception

My records show a GLA variant treatable with migalastat.

I have end-stage renal disease and will complete all my dialysis sessions as prescribed.

Exclusion Criteria

I am allergic to migalastat or similar medications.

I do not have any health conditions that would stop me from following the study's requirements.

Subject is treated or has been treated with another investigational drug (except migalastat) within the 30 days

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Baseline

Baseline visit to confirm enrollment eligibility and conduct initial assessments

Within 30 days of screening

1 visit (in-person)

Treatment

Participants receive migalastat based on their cohort assignment and eGFRMDRD result

12 months

Regular visits as per dosing schedule

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Migalastat HCl

Trial Overview The study tests the safety and how the body processes Migalastat HCl in individuals with Fabry disease who also have severe renal impairment (SRI) or are at the end stage of renal disease (ESRD). It's an open-label study where all participants know they're receiving Migalastat.

Participant Groups

Group I: Cohort 2: End-Stage Renal Disease Experimental Treatment 1 Intervention

All hemodialysis subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat). Subjects will take 1 migalastat capsule orally with water every other week.

Group II: Cohort 1: Severe Renal Impairment Experimental Treatment 1 Intervention

All subjects will receive migalastat 123 mg, equivalent to 150 mg migalastat HCl (hereafter, migalastat) at a dose regimen based on their eGFRMDRD result at Visit 1. Subjects will take 1 migalastat capsule orally with water either every 4 or 7 days.

Migalastat HCl is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:

Approved in European Union as Galafold for:

• Fabry disease

Approved in United States as Galafold for:

• Fabry disease

Approved in Canada as Galafold for:

• Fabry disease

Approved in Japan as Galafold for:

• Fabry disease

Approved in Switzerland as Galafold for:

• Fabry disease

Who Is Running the Clinical Trial?

Amicus Therapeutics

Lead Sponsor

Trials

55

Recruited

2,700+

Findings from Research

Migalastat (Galafold™) has been approved in the EU for treating Fabry disease in patients with specific mutations that allow the drug to restore α-galactosidase activity.

Fabry disease is caused by a deficiency of α-galactosidase, leading to harmful accumulation of certain substances in cells, and migalastat offers a targeted treatment option for this rare disorder.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Migalastat: First Global Approval. Markham, A.[2018]

Migalastat (Galafold®) is an effective oral treatment for Fabry disease that can improve enzyme activity in patients with specific mutations, showing benefits such as reduced left ventricular mass and stabilized kidney function.

Switching from traditional enzyme replacement therapy to migalastat has been shown to be safe and effective, with positive outcomes observed in both treatment-naive patients and those previously on enzyme replacement therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today? Perretta, F., Jaurretche, S.[2023]

Migalastat is a novel oral treatment for Fabry disease that works by stabilizing mutant forms of the enzyme alpha-galactosidase A, allowing them to function better and reduce harmful substance accumulation in cells.

In pivotal Phase III studies, migalastat showed promising results, being more effective than enzyme replacement therapy in reducing left ventricular mass in patients with cardiac hypertrophy, while also demonstrating comparable effects on kidney function.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Chaperone molecules: The example of Fabry disease]. Barbey, F., Monney, P., Dormond, O.[2021]

Migalastat (Galafold™) is the first approved oral pharmacological chaperone for treating Fabry disease in patients with specific GLA mutations, showing significant efficacy in reducing kidney globotriaosylceramide (GL-3) inclusions and plasma lyso-globotriaosylsphingosine levels after 6 months in amenable patients.

In trials, migalastat maintained renal function and reduced cardiac mass over 18 months compared to enzyme replacement therapy (ERT), demonstrating its potential as a well-tolerated treatment option for Fabry disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Migalastat: A Review in Fabry Disease. McCafferty, EH., Scott, LJ.[2020]

In the phase 3 FACETS trial, migalastat showed clinical benefits in patients with Fabry disease, particularly in those with the classic phenotype, where significant improvements were observed in kidney function and other health markers after 24 months.

Patients with the classic phenotype experienced a decrease in harmful globotriaosylceramide inclusions and improvements in left ventricular mass and gastrointestinal symptoms, indicating that migalastat is effective regardless of the severity of the disease.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Germain, DP., Nicholls, K., Giugliani, R., et al.[2022]

In an eight-year study involving 92 patients, intermittent high-dose liposomal Amphotericin B (L-AmB) was found to have manageable and reversible toxicity, with hypokalaemia being the most common serious side effect in 23% of treatment courses.

Breakthrough invasive fungal infections (IFI) were rare, occurring in only 1.8% of cases, suggesting that L-AmB is an effective prophylactic option for high-risk haemato-oncology patients who cannot use triazoles due to drug interactions or toxicities.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature. Youngs, J., Low, JM., Whitney, L., et al.[2021]

Migalastat is an approved treatment for Fabry disease, but the effectiveness of this drug can vary based on the specific mutations present in patients, with 367 known amenable mutations and 711 non-amenable mutations.

Current in vitro assays used to determine mutation amenability may not accurately predict in vivo responses, leading to discrepancies that require physicians to closely monitor patient responses to treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

In Vitro and In Vivo Amenability to Migalastat in Fabry Disease. Lenders, M., Stappers, F., Brand, E.[2020]

In a study of 78 patients with Fabry disease treated with migalastat for at least 2 years, long-term treatment was associated with stable renal function, as indicated by minimal changes in estimated glomerular filtration rate (eGFR) regardless of whether patients were naive to enzyme replacement therapy (ERT) or had prior ERT experience.

Both ERT-naive and ERT-experienced patients showed similar annualized rates of change in eGFR, suggesting that migalastat effectively maintains renal function over time, with no significant differences based on sex or disease phenotype.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Bichet, DG., Torra, R., Wallace, E., et al.[2023]

Fungisome® (F), a liposomal amphotericin B product, showed significant antileishmanial activity in a murine model of cutaneous leishmaniasis, but its efficacy was lower than that of the standard treatment, AmBisome® (A).

At higher doses (15 mg/kg), Fungisome® exhibited clear signs of toxicity, indicating potential safety concerns, while AmBisome® did not show such toxicity, suggesting that Fungisome® may be less safe and effective compared to AmBisome® for treating cutaneous leishmaniasis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis. Wijnant, GJ., Van Bocxlaer, K., Yardley, V., et al.[2021]

Liposomal nystatin (Nyotran) demonstrated comparable antifungal activity to free nystatin against various fungal species, showing both fungistatic and fungicidal effects, which were similar to or lower than those of free nystatin.

While liposomal nystatin was not as effective as amphotericin B formulations, it outperformed liposomal amphotericin B, indicating that further research into liposomal nystatin's potential as an antifungal treatment is warranted.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Johnson, EM., Ojwang, JO., Szekely, A., et al.[2020]

Migalastat hydrochloride, an oral treatment for Fabry disease, was well tolerated and showed increased α-galactosidase A (α-Gal A) activity in 6 out of 9 patients, indicating its potential efficacy.

The treatment led to a reduction in globotriaosylceramide (GL-3) levels in patients with specific mutations that responded to the drug, suggesting a genotype-specific mechanism of action.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Germain, DP., Giugliani, R., Hughes, DA., et al.[2021]

In a study involving 57 adults with Fabry disease, migalastat, an oral treatment, showed similar effects on renal function compared to traditional intravenous enzyme replacement therapy (ERT) over 18 months.

Migalastat treatment led to a significant reduction in left ventricular mass index, indicating potential heart health benefits, while ERT did not show this effect, suggesting migalastat may be a promising alternative for patients with amenable mutations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Hughes, DA., Nicholls, K., Shankar, SP., et al.[2022]

References

1. New Zealand pubmed.ncbi.nlm.nih.gov

Migalastat: First Global Approval. [2018]

2. Switzerland pubmed.ncbi.nlm.nih.gov

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today? [2023]

3. France pubmed.ncbi.nlm.nih.gov

[Chaperone molecules: The example of Fabry disease]. [2021]

4. New Zealand pubmed.ncbi.nlm.nih.gov

Migalastat: A Review in Fabry Disease. [2020]

5. United States pubmed.ncbi.nlm.nih.gov

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. [2022]

6. Switzerland pubmed.ncbi.nlm.nih.gov

Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature. [2021]

7. United States pubmed.ncbi.nlm.nih.gov

In Vitro and In Vivo Amenability to Migalastat in Fabry Disease. [2020]

8. United States pubmed.ncbi.nlm.nih.gov

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. [2023]

9. Netherlands pubmed.ncbi.nlm.nih.gov

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis. [2021]

10. United States pubmed.ncbi.nlm.nih.gov

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. [2020]

11. England pubmed.ncbi.nlm.nih.gov

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. [2021]

12. England pubmed.ncbi.nlm.nih.gov

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. [2022]